Search
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.
Burosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalThis is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets.
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigationalhigh dose by rapid intravenous injection [L2181]. … [L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain.
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions
Tagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigational[A253762] It was also approved by the European Commission on January 7, 2021.[L43712] … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is
Omega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalα-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by
Mixtures: K-OMEGASQUA (Softgel)Zotepine
go.drugbank.com/drugs/DB09225ApprovedWithdrawnIt was designed and synthesized by Fujisawa Pharmaceutical Co Ltd.[A31855] It has been used as an antipsychotic in Japan, India and some places in Europe like UK and Germany since 1980's. … In 1993, it was classified as inactive drug substance (Status I, Type II) and in 1995 the FDA studied the manufacturing procedures of Zotepine tablets in Germany, but the status remained inactive.
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigational[A19739] Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Montelukast
go.drugbank.com/drugs/DB00471ApprovedInvestigationalMontelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive